CRESP 60

Anemia

Description
Shipping Options
Customer Reviews

1. Definition & Composition

Generic Name: Darbepoetin Alfa
Strength: 60 mcg per dose (single-use vial/prefilled syringe)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Composition:
- Active: Darbepoetin Alfa (recombinant glycoprotein)
- Excipients: Sodium phosphate, polysorbate 80, sucrose (stabilizers)

2. Importance

Treats anemia in:
- Chronic Kidney Disease (CKD) (dialysis/non-dialysis)
- Chemotherapy-induced anemia (non-myeloid cancers)
Reduces transfusion dependency
Longer half-life than EPO → Less frequent dosing (weekly/biweekly)

3. Uses (Indications)

✅ Approved:

CKD-related anemia (Hb <10 g/dL)
Cancer patients on chemotherapy (Hb <10 g/dL) 🚫 Not for:
Anemia due to iron/B12/folate deficiency (correct deficiencies first).
Anemia in myeloid cancers (e.g., AML, CML).

4. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Target Hb: 10–12 g/dL (Never >12 g/dL → ↑ thrombosis risk).
Iron Supplementation: Required if ferritin <100 ng/mL.

5. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site reactions (pain, swelling)
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Major risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

6. Storage & Handling

Temperature: Refrigerate at 2–8°C (Do not freeze).
Light Protection: Keep in original carton.
Shaking: Avoid – causes protein denaturation.
Expiry: Discard unused portions (single-dose vial).

7. Contraindications & Warnings

❌ Avoid in:

Uncontrolled hypertension
PRCA post-ESA therapy
Hypersensitivity to darbepoetin

⚠️ FDA Black Box Warning:

↑ Risk of death, thrombosis, and tumor progression (in cancer patients).

8. Conclusion

CRESP 60 (Darbepoetin Alfa 60 mcg) is a high-dose ESA for severe anemia in CKD and chemotherapy patients. While effective, it demands:

Strict Hb monitoring (10–12 g/dL).
Iron status checks (ferritin, TSAT).
Specialist supervision to mitigate risks (thrombosis, PRCA).

For Best Outcomes:

Use the lowest effective dose.
Combine with iron therapy if deficient.
Avoid in curable cancers (may worsen survival).

1. Definition & Composition

Generic Name: Darbepoetin Alfa
Strength: 60 mcg per dose (single-use vial/prefilled syringe)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Composition:
- Active: Darbepoetin Alfa (recombinant glycoprotein)
- Excipients: Sodium phosphate, polysorbate 80, sucrose (stabilizers)

2. Importance

Treats anemia in:
- Chronic Kidney Disease (CKD) (dialysis/non-dialysis)
- Chemotherapy-induced anemia (non-myeloid cancers)
Reduces transfusion dependency
Longer half-life than EPO → Less frequent dosing (weekly/biweekly)

3. Uses (Indications)

✅ Approved:

CKD-related anemia (Hb <10 g/dL)
Cancer patients on chemotherapy (Hb <10 g/dL)
🚫 Not for:
Anemia due to iron/B12/folate deficiency (correct deficiencies first).
Anemia in myeloid cancers (e.g., AML, CML).

4. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Target Hb: 10–12 g/dL (Never >12 g/dL → ↑ thrombosis risk).
Iron Supplementation: Required if ferritin <100 ng/mL.

5. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site reactions (pain, swelling)
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Major risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

6. Storage & Handling

Temperature: Refrigerate at 2–8°C (Do not freeze).
Light Protection: Keep in original carton.
Shaking: Avoid – causes protein denaturation.
Expiry: Discard unused portions (single-dose vial).

7. Contraindications & Warnings

❌ Avoid in:

Uncontrolled hypertension
PRCA post-ESA therapy
Hypersensitivity to darbepoetin

⚠️ FDA Black Box Warning:

↑ Risk of death, thrombosis, and tumor progression (in cancer patients).

8. Conclusion

CRESP 60 (Darbepoetin Alfa 60 mcg) is a high-dose ESA for severe anemia in CKD and chemotherapy patients. While effective, it demands:

Strict Hb monitoring (10–12 g/dL).
Iron status checks (ferritin, TSAT).
Specialist supervision to mitigate risks (thrombosis, PRCA).

For Best Outcomes:

Use the lowest effective dose.
Combine with iron therapy if deficient.
Avoid in curable cancers (may worsen survival).

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

1. Definition & Composition

Generic Name: Darbepoetin Alfa
Strength: 60 mcg per dose (single-use vial/prefilled syringe)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Composition:
- Active: Darbepoetin Alfa (recombinant glycoprotein)
- Excipients: Sodium phosphate, polysorbate 80, sucrose (stabilizers)

2. Importance

Treats anemia in:
- Chronic Kidney Disease (CKD) (dialysis/non-dialysis)
- Chemotherapy-induced anemia (non-myeloid cancers)
Reduces transfusion dependency
Longer half-life than EPO → Less frequent dosing (weekly/biweekly)

3. Uses (Indications)

✅ Approved:

CKD-related anemia (Hb <10 g/dL)
Cancer patients on chemotherapy (Hb <10 g/dL)
🚫 Not for:
Anemia due to iron/B12/folate deficiency (correct deficiencies first).
Anemia in myeloid cancers (e.g., AML, CML).

4. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Target Hb: 10–12 g/dL (Never >12 g/dL → ↑ thrombosis risk).
Iron Supplementation: Required if ferritin <100 ng/mL.

5. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site reactions (pain, swelling)
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Major risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

6. Storage & Handling

Temperature: Refrigerate at 2–8°C (Do not freeze).
Light Protection: Keep in original carton.
Shaking: Avoid – causes protein denaturation.
Expiry: Discard unused portions (single-dose vial).

7. Contraindications & Warnings

❌ Avoid in:

Uncontrolled hypertension
PRCA post-ESA therapy
Hypersensitivity to darbepoetin

⚠️ FDA Black Box Warning:

↑ Risk of death, thrombosis, and tumor progression (in cancer patients).

8. Conclusion

CRESP 60 (Darbepoetin Alfa 60 mcg) is a high-dose ESA for severe anemia in CKD and chemotherapy patients. While effective, it demands:

Strict Hb monitoring (10–12 g/dL).
Iron status checks (ferritin, TSAT).
Specialist supervision to mitigate risks (thrombosis, PRCA).

For Best Outcomes:

Use the lowest effective dose.
Combine with iron therapy if deficient.
Avoid in curable cancers (may worsen survival).

Reviews

There are no reviews yet.

Be the first to review “CRESP 60”

Description
Reviews (0)

1. Definition & Composition

Generic Name: Darbepoetin Alfa
Strength: 60 mcg per dose (single-use vial/prefilled syringe)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Composition:
- Active: Darbepoetin Alfa (recombinant glycoprotein)
- Excipients: Sodium phosphate, polysorbate 80, sucrose (stabilizers)

2. Importance

Treats anemia in:
- Chronic Kidney Disease (CKD) (dialysis/non-dialysis)
- Chemotherapy-induced anemia (non-myeloid cancers)
Reduces transfusion dependency
Longer half-life than EPO → Less frequent dosing (weekly/biweekly)

3. Uses (Indications)

✅ Approved:

CKD-related anemia (Hb <10 g/dL)
Cancer patients on chemotherapy (Hb <10 g/dL)
🚫 Not for:
Anemia due to iron/B12/folate deficiency (correct deficiencies first).
Anemia in myeloid cancers (e.g., AML, CML).

4. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Target Hb: 10–12 g/dL (Never >12 g/dL → ↑ thrombosis risk).
Iron Supplementation: Required if ferritin <100 ng/mL.

5. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site reactions (pain, swelling)
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Major risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

6. Storage & Handling

Temperature: Refrigerate at 2–8°C (Do not freeze).
Light Protection: Keep in original carton.
Shaking: Avoid – causes protein denaturation.
Expiry: Discard unused portions (single-dose vial).

7. Contraindications & Warnings

❌ Avoid in:

Uncontrolled hypertension
PRCA post-ESA therapy
Hypersensitivity to darbepoetin

⚠️ FDA Black Box Warning:

↑ Risk of death, thrombosis, and tumor progression (in cancer patients).

8. Conclusion

CRESP 60 (Darbepoetin Alfa 60 mcg) is a high-dose ESA for severe anemia in CKD and chemotherapy patients. While effective, it demands:

Strict Hb monitoring (10–12 g/dL).
Iron status checks (ferritin, TSAT).
Specialist supervision to mitigate risks (thrombosis, PRCA).

For Best Outcomes:

Use the lowest effective dose.
Combine with iron therapy if deficient.
Avoid in curable cancers (may worsen survival).

Reviews

There are no reviews yet.

Be the first to review “CRESP 60”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.